SI2114935T1 - Piperidinski gpcr-agonisti - Google Patents
Piperidinski gpcr-agonistiInfo
- Publication number
- SI2114935T1 SI2114935T1 SI200830401T SI200830401T SI2114935T1 SI 2114935 T1 SI2114935 T1 SI 2114935T1 SI 200830401 T SI200830401 T SI 200830401T SI 200830401 T SI200830401 T SI 200830401T SI 2114935 T1 SI2114935 T1 SI 2114935T1
- Authority
- SI
- Slovenia
- Prior art keywords
- gpcr agonists
- piperidine
- piperidine gpcr
- agonists
- gpcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700125A GB0700125D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
GB0708746A GB0708746D0 (en) | 2007-05-08 | 2007-05-08 | GPCR agonists |
GB0719763A GB0719763D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
PCT/GB2008/050013 WO2008081207A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
EP08702096A EP2114935B1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2114935T1 true SI2114935T1 (sl) | 2011-11-30 |
Family
ID=39199058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200830401T SI2114935T1 (sl) | 2007-01-04 | 2008-01-04 | Piperidinski gpcr-agonisti |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100105732A1 (sl) |
EP (2) | EP2114935B1 (sl) |
JP (1) | JP2010514831A (sl) |
AR (1) | AR064735A1 (sl) |
AT (1) | ATE517103T1 (sl) |
BR (1) | BRPI0806500A2 (sl) |
CA (1) | CA2674455A1 (sl) |
CL (1) | CL2008000018A1 (sl) |
CY (1) | CY1112474T1 (sl) |
DK (1) | DK2114935T3 (sl) |
EA (1) | EA015130B1 (sl) |
HK (1) | HK1135705A1 (sl) |
HR (1) | HRP20110750T1 (sl) |
PE (1) | PE20081659A1 (sl) |
PL (1) | PL2114935T3 (sl) |
PT (1) | PT2114935E (sl) |
RS (1) | RS51943B (sl) |
SA (1) | SA08280757B1 (sl) |
SI (1) | SI2114935T1 (sl) |
TW (1) | TW200835482A (sl) |
WO (1) | WO2008081207A1 (sl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080312281A1 (en) * | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
NZ564759A (en) * | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
AR064736A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
EP2200609A1 (en) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
CN104016970A (zh) | 2007-10-10 | 2014-09-03 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812641D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
EP2379542B1 (en) * | 2008-12-24 | 2013-02-13 | Cadila Healthcare Limited | Novel oxime derivatives |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
AU2010264720A1 (en) | 2009-06-24 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN104610390A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途 |
CN104610393A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
FR2705346B1 (fr) * | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
CA2229617A1 (en) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
ZA977103B (en) | 1996-08-09 | 1999-02-08 | Eisai Co Ltd | Benzopiperidine derivatives |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
AU5700999A (en) | 1998-09-01 | 2000-03-21 | Basf Aktiengesellschaft | Enhanced functional expression of g protein-coupled receptors |
US6221660B1 (en) * | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
WO2003020217A2 (en) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
CN1206220C (zh) * | 2000-11-21 | 2005-06-15 | 三菱化学株式会社 | 生产2-(4-吡啶基)乙硫醇的方法 |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
UA78523C2 (en) | 2001-09-21 | 2007-04-10 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
PL367814A1 (en) | 2001-09-21 | 2005-03-07 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
JP2005531520A (ja) | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換2,3−ジフェニルピリジン類 |
CA2480856A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
CA2481313A1 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
RU2304580C2 (ru) | 2002-07-29 | 2007-08-20 | Ф.Хоффманн-Ля Рош Аг | Новые бензодиоксолы |
ES2294330T3 (es) | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
AU2003296895A1 (en) | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
AR041268A1 (es) | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
JP2006506366A (ja) | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
WO2004058145A2 (en) | 2002-12-19 | 2004-07-15 | Merck & Co., Inc. | Substituted amides |
GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
EP1583762B1 (en) | 2003-01-02 | 2008-07-09 | F. Hoffmann-La Roche Ag | Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists |
US7294644B2 (en) | 2003-01-02 | 2007-11-13 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
KR20050100686A (ko) | 2003-02-13 | 2005-10-19 | 사노피-아벤티스 도이칠란트 게엠베하 | 질소-치환된헥사하이드로피라지노[1,2-a]피리미딘-4,7-디온 유도체,이의 제조방법 및 의약으로서의 이의 용도 |
ATE472548T1 (de) | 2003-02-13 | 2010-07-15 | Sanofi Aventis Deutschland | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
EP1606019A1 (en) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
EP1711491A1 (en) | 2003-12-24 | 2006-10-18 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
US20080312281A1 (en) | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
MX2007016545A (es) | 2005-06-30 | 2008-02-21 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
EP1907383A1 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
BRPI0710839A2 (pt) * | 2006-04-06 | 2011-08-23 | Prosidion Ltd | agonistas heterocìclicos de gpcr |
CN101657471B (zh) * | 2006-12-06 | 2013-07-03 | 史密丝克莱恩比彻姆公司 | 二环化合物及其作为抗糖尿病药的用途 |
AR064736A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
-
2008
- 2008-01-03 PE PE2008000084A patent/PE20081659A1/es not_active Application Discontinuation
- 2008-01-03 AR ARP080100017A patent/AR064735A1/es unknown
- 2008-01-03 CL CL200800018A patent/CL2008000018A1/es unknown
- 2008-01-04 US US12/522,023 patent/US20100105732A1/en not_active Abandoned
- 2008-01-04 JP JP2009544450A patent/JP2010514831A/ja active Pending
- 2008-01-04 WO PCT/GB2008/050013 patent/WO2008081207A1/en active Application Filing
- 2008-01-04 BR BRPI0806500-4A2A patent/BRPI0806500A2/pt not_active IP Right Cessation
- 2008-01-04 EP EP08702096A patent/EP2114935B1/en active Active
- 2008-01-04 AT AT08702096T patent/ATE517103T1/de active
- 2008-01-04 EP EP11169308A patent/EP2377864A1/en not_active Withdrawn
- 2008-01-04 EA EA200900880A patent/EA015130B1/ru not_active IP Right Cessation
- 2008-01-04 CA CA002674455A patent/CA2674455A1/en not_active Abandoned
- 2008-01-04 RS RS20110448A patent/RS51943B/en unknown
- 2008-01-04 DK DK08702096.2T patent/DK2114935T3/da active
- 2008-01-04 TW TW097100416A patent/TW200835482A/zh unknown
- 2008-01-04 PT PT08702096T patent/PT2114935E/pt unknown
- 2008-01-04 PL PL08702096T patent/PL2114935T3/pl unknown
- 2008-01-04 SI SI200830401T patent/SI2114935T1/sl unknown
- 2008-01-05 SA SA8280757A patent/SA08280757B1/ar unknown
-
2010
- 2010-04-16 HK HK10103733.4A patent/HK1135705A1/xx not_active IP Right Cessation
-
2011
- 2011-10-14 HR HR20110750T patent/HRP20110750T1/hr unknown
- 2011-10-17 CY CY20111100985T patent/CY1112474T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008081207A1 (en) | 2008-07-10 |
JP2010514831A (ja) | 2010-05-06 |
EP2377864A1 (en) | 2011-10-19 |
BRPI0806500A2 (pt) | 2014-04-22 |
HRP20110750T1 (hr) | 2011-11-30 |
CY1112474T1 (el) | 2015-12-09 |
TW200835482A (en) | 2008-09-01 |
PL2114935T3 (pl) | 2012-03-30 |
PT2114935E (pt) | 2011-10-17 |
DK2114935T3 (da) | 2011-10-31 |
PE20081659A1 (es) | 2008-10-24 |
CA2674455A1 (en) | 2008-07-10 |
AR064735A1 (es) | 2009-04-22 |
EP2114935B1 (en) | 2011-07-20 |
EA015130B1 (ru) | 2011-06-30 |
US20100105732A1 (en) | 2010-04-29 |
ATE517103T1 (de) | 2011-08-15 |
EA200900880A1 (ru) | 2010-02-26 |
HK1135705A1 (en) | 2010-06-11 |
RS51943B (en) | 2012-02-29 |
SA08280757B1 (ar) | 2011-01-15 |
EP2114935A1 (en) | 2009-11-11 |
CL2008000018A1 (es) | 2008-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1135704A1 (en) | Piperidine gpcr agonists | |
HK1135705A1 (en) | Piperidine gpcr agonists | |
IL209978A0 (en) | Piperidinyl gpcr agonists | |
GB0700122D0 (en) | GPCR agonists | |
ZA200809289B (en) | Heterocyclic gpcr agonists | |
EP2311822A4 (en) | GPR119 AGONIST | |
EP2173174A4 (en) | FARNESOID X RECEPTOR AGONISTS | |
EP2170072A4 (en) | Farnesoid X RECEPTOR AGONISTS | |
EP2151236A4 (en) | G PROTEIN COUPLED RECEPTOR AGONIST | |
IL202616A0 (en) | Substituted imidazoheterocycles | |
ZA201103154B (en) | Melanocortin receptor agonists | |
EP2041120A4 (en) | MELANOCORTIN RECEPTOR AGONISTS | |
IL200845A0 (en) | Oligomer-opoid agonist conjugates | |
IL201165A0 (en) | CRIg ANTAGONISTS | |
GB0708226D0 (en) | Y-receptor agonists | |
IL200965A0 (en) | Substituted tetrahydropyrroloquinolines | |
GB0719765D0 (en) | GPCR agonists | |
GB0700124D0 (en) | GPCR agonists | |
GB0708748D0 (en) | GPCR agonists | |
GB0708746D0 (en) | GPCR agonists | |
GB0719763D0 (en) | GPCR agonists | |
GB0719760D0 (en) | GPCR agonists | |
GB0700125D0 (en) | GPCR agonists | |
GB0700123D0 (en) | GPCR agonists | |
GB0700126D0 (en) | GPCR agonists |